CardiovascularFDA Approved

Nesiritide (Natrecor)

Intravenous

Overview

A recombinant form of human B-type natriuretic peptide (BNP), a 32-amino acid peptide naturally produced by ventricular cardiomyocytes in response to volume overload and wall stress.

Mechanism of Action

Nesiritide binds natriuretic peptide receptor A (NPR-A), activating guanylyl cyclase and increasing intracellular cGMP to produce venous, arterial, and coronary vasodilation, natriuresis, and suppression of the renin-angiotensin-aldosterone and sympathetic nervous systems..

Research Summary & Key Findings

FDA-approved in 2001 for acutely decompensated heart failure with dyspnea at rest. ASCEND-HF trial (2011) showed modest improvement in dyspnea but no reduction in mortality or rehospitalization, with trends toward worsening renal function and hypotension. Use has declined significantly in favor of other heart failure therapies. Remains available but relegated to second-line status by current guidelines.

Clinical Status

FDA Approved

Nesiritide (Natrecor) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Intravenous

Related Peptides in Cardiovascular

Find a Provider

Find a verified provider who offers Nesiritide (Natrecor) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Nesiritide (Natrecor).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.